We are live on ! Find out more
RARX

Ra Pharmaceuticals, Inc. Common Stock
RARX

Delisted

RARX was delisted on the 1st of April, 2020.

Back to rankings

1 hedge funds and large institutions have $32K invested in Ra Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 142 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 144 → 1 (-143)

100% less funds holding in top 10

Funds holding in top 10: 11 → 0 (-11)

100% less capital invested

Capital invested by funds: $2.47B → $32K (-$2.47B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 142

Holders
1
Holders Change
-143
Holders Change %
-99.31%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-11
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
142
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$295M
2
RCM
RA Capital Management
Massachusetts
-$233M
3
BlackRock
BlackRock
New York
-$213M
4
BBA
Baker Bros. Advisors
New York
-$101M
5
AAM
Alpine Associates Management
Florida
-$96.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
101
VOYA Investment Management
Georgia
– -$843K -17,559 Closed
Deutsche Bank
102
Deutsche Bank
Germany
– -$804K -16,750 Closed
State Board of Administration of Florida Retirement System
103
State Board of Administration of Florida Retirement System
Florida
– -$804K -16,741 Closed
Nisa Investment Advisors
104
Nisa Investment Advisors
Missouri
– -$775K -16,140 Closed
GC
105
Guggenheim Capital
Illinois
– -$742K -15,461 Closed
AA
106
Ancora Advisors
Ohio
– -$720K -15,000 Closed
TI
107
Telemetry Investments
New York
– -$720K -15,000 Closed
MIM
108
MetLife Investment Management
New Jersey
– -$703K -14,651 Closed
Jane Street
109
Jane Street
New York
– -$580K -12,073 Closed
PCM
110
Prelude Capital Management
New York
– -$571K -11,900 Closed
HF
111
HRT Financial
New York
– -$527K -10,981 Closed
MLICM
112
Metropolitan Life Insurance Company (MetLife)
New York
– -$509K -10,600 Closed
T. Rowe Price Associates
113
T. Rowe Price Associates
Maryland
– -$463K -9,640 Closed
CANY
114
Caxton Associates (New York)
New York
– -$434K -9,049 Closed
ProShare Advisors
115
ProShare Advisors
Maryland
– -$409K -8,522 Closed
VEA
116
Virtus ETF Advisers
New York
– -$365K -7,612 Closed
SSA
117
Schonfeld Strategic Advisors
New York
– -$349K -7,264 Closed
ASRS
118
Arizona State Retirement System
Arizona
– -$345K -7,194 Closed
GCP
119
GSA Capital Partners
United Kingdom
– -$332K -6,915 Closed
DMK
120
David M. Knott
– -$307K -6,400 Closed
AB
121
Amalgamated Bank
New York
– -$300K -6,259 Closed
Invesco
122
Invesco
Georgia
– -$277K -5,776 Closed
Rafferty Asset Management
123
Rafferty Asset Management
New York
– -$277K -5,775 Closed
Public Employees Retirement Association of Colorado
124
Public Employees Retirement Association of Colorado
Colorado
– -$232K -4,825 Closed
Principal Financial Group
125
Principal Financial Group
Iowa
– -$212K -4,414 Closed
2 3 4
5
6

RARX Hedge Fund Activity: Q2 2020 in Review

1 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q2 2020, worth a combined $32K — down 100% from $2.47B a quarter earlier.

Sellers outnumbered buyers: 142 funds closed out of RARX and 0 opened new positions — a net loss of 142 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was NEA Management Company, exiting entirely with an estimated $295M sold.

  • 1 institutional investor held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q2 2020, down from 144 in Q1 2020.
  • Funds reported $32K of Ra Pharmaceuticals, Inc. Common Stock stock for Q2 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 142 closed out, a net change of -142 holders.
  • The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was NEA Management Company, an estimated $295M sold.

Based on aggregated 13F filings for Q2 2020.